Clinical Advances in Myeloid Malignancies

CME

Congress to Clinic: Myeloid Malignancies Clinical Advances Journal Club on Emerging MPN, MDS, and AML Data

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: July 19, 2024

Expiration: July 18, 2025

Courtney DiNardo
Courtney DiNardo, MD, MSCE
Brady L. Stein
Brady L. Stein, MD, MHS
Eunice S. Wang
Eunice S. Wang, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

As compared to ESA therapy in a randomized trial, which of the following agents improved the time to first RBC transfusion in previously untreated very-low to intermediate-risk MDS?

2.

Based on the latest clinical advances in AML, which of the following regimens might be a preferred option for young and fit patients with newly diagnosed favorable/intermediate-risk AML?

3.

You are planning treatment for PV. Which of the following medications for patients with PV has shown molecular responses that correlate with improved clinical outcomes?